The diabetes and weight loss drug market is heating up in 2025, with significant growth signs everywhere. According to a recent study from Research and Markets, industry growth is running at an ...

These equities have substantial upside potential and, should clinical studies be successful, offer an “option-like structure ... particularly for VK2735, an obesity treatment.

It maintains $1.3 billion in liquidity for flexibility and is actively working to diversify its capital structure ... for hip fracture recovery, and VK2735 for weight loss, it’s advancing ...

“What the FDA is saying is that they’re recognizing obesity is a real health crisis,” Ray Stevens, CEO of Structure Therapeutics ... s Phase III study design for its obesity candidate VK2735. Obesity ...

Viking Therapeutics has initiated a ~280-patient phase 2a study of oral VK2735, with management guiding for a result in H2'25. Previous trials of VK2735 have enrolled ahead of schedule ...

Partnership is expected to support Phase III development of VK2735 in patients with obesity and metabolic disorders amid increasing demand for GLP-1 therapy. Viking Therapeutics has signed a long-term ...

The agreement provides Viking with sufficient long-term supply of both subcutaneous and oral VK2735 product forms to support a potential multi-billion-dollar annual product opportunity.